Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and pipeline support a wide moat, but Gilead needs strong continued innovation in HIV, solid oncology launches, and smart future acquisitions to guarantee mid-single-digit growth over our 10-year forecast.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.06 | 45.36 | 11.46 |
Price/Book Value | 15.86 | 8.57 | 3.98 |
Price/Sales | 6.19 | 5.43 | 2.13 |
Price/Cash Flow | 12.47 | 16.30 | 9.11 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.75 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | −1.28 | 4.28 | 9.51 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.75% | 6.27% | 11.66% |
Return on Equity (Normalized) | −2.11% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 0.26% | 9.82% | 22.63% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|$Y&#pFp | LOCK|c# | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|vs%BfG | LOCK|F! | $630B | |||
| AbbVie Inc
ABBV
| LOCK|x$>$^<< | LOCK|kg | $489B | |||
| Merck & Co Inc
MRK
| LOCK|^Nl^?b | LOCK|X!q | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|Nj>%ct% | LOCK|dC | $344B | |||
| Novartis AG ADR
NVS
| LOCK|Bb#@?W@R | LOCK|Z$s | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|&qqVw^VY | LOCK|Np@ | $246B | |||
| Amgen Inc
AMGN
| LOCK|l$>?<z> | LOCK|<! | $224B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|VsV!@pq | LOCK|tc | $169B |
United States